Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) Shares Sold by Strs Ohio

Strs Ohio decreased its stake in Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) by 14.0% during the 4th quarter, Holdings Channel reports. The firm owned 16,000 shares of the company’s stock after selling 2,600 shares during the quarter. Strs Ohio’s holdings in Amphastar Pharmaceuticals were worth $989,000 at the end of the most recent reporting period.

Other institutional investors have also modified their holdings of the company. Louisiana State Employees Retirement System purchased a new position in shares of Amphastar Pharmaceuticals in the fourth quarter worth about $1,157,000. Shaker Investments LLC OH lifted its stake in shares of Amphastar Pharmaceuticals by 136.0% in the fourth quarter. Shaker Investments LLC OH now owns 49,078 shares of the company’s stock worth $3,035,000 after buying an additional 28,283 shares in the last quarter. Perigon Wealth Management LLC lifted its stake in shares of Amphastar Pharmaceuticals by 153.0% in the fourth quarter. Perigon Wealth Management LLC now owns 12,102 shares of the company’s stock worth $749,000 after buying an additional 7,319 shares in the last quarter. Leeward Financial Partners LLC purchased a new position in shares of Amphastar Pharmaceuticals in the fourth quarter worth about $217,000. Finally, Moody Aldrich Partners LLC purchased a new position in shares of Amphastar Pharmaceuticals in the fourth quarter worth about $3,904,000. Institutional investors and hedge funds own 65.09% of the company’s stock.

Amphastar Pharmaceuticals Price Performance

Shares of AMPH stock opened at $40.91 on Wednesday. Amphastar Pharmaceuticals, Inc. has a 12 month low of $35.62 and a 12 month high of $67.66. The company has a market capitalization of $2.00 billion, a PE ratio of 15.86, a price-to-earnings-growth ratio of 0.95 and a beta of 0.85. The firm’s 50-day moving average is $45.36 and its two-hundred day moving average is $51.09. The company has a debt-to-equity ratio of 0.92, a current ratio of 2.17 and a quick ratio of 1.70.

Amphastar Pharmaceuticals (NASDAQ:AMPH) last announced its quarterly earnings results on Wednesday, February 28th. The company reported $0.81 earnings per share for the quarter, missing analysts’ consensus estimates of $0.84 by ($0.03). Amphastar Pharmaceuticals had a net margin of 21.34% and a return on equity of 26.95%. The company had revenue of $178.11 million for the quarter, compared to analyst estimates of $174.90 million. Analysts predict that Amphastar Pharmaceuticals, Inc. will post 3.43 earnings per share for the current year.

Analysts Set New Price Targets

AMPH has been the topic of several research reports. StockNews.com downgraded shares of Amphastar Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Thursday, February 29th. Needham & Company LLC reissued a “hold” rating on shares of Amphastar Pharmaceuticals in a research note on Wednesday, April 10th. Finally, JPMorgan Chase & Co. initiated coverage on shares of Amphastar Pharmaceuticals in a research note on Tuesday, March 5th. They set an “overweight” rating and a $60.00 target price on the stock. Three analysts have rated the stock with a hold rating and two have given a buy rating to the stock. Based on data from MarketBeat, the stock has a consensus rating of “Hold” and an average target price of $66.00.

Insider Buying and Selling at Amphastar Pharmaceuticals

In other Amphastar Pharmaceuticals news, Director Floyd F. Petersen sold 500 shares of Amphastar Pharmaceuticals stock in a transaction dated Thursday, February 1st. The shares were sold at an average price of $53.10, for a total transaction of $26,550.00. Following the completion of the sale, the director now directly owns 80,333 shares in the company, valued at $4,265,682.30. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. In other Amphastar Pharmaceuticals news, Director Floyd F. Petersen sold 500 shares of Amphastar Pharmaceuticals stock in a transaction dated Thursday, February 1st. The shares were sold at an average price of $53.10, for a total transaction of $26,550.00. Following the completion of the sale, the director now directly owns 80,333 shares in the company, valued at $4,265,682.30. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, Director Michael A. Zasloff sold 12,500 shares of Amphastar Pharmaceuticals stock in a transaction dated Tuesday, March 5th. The shares were sold at an average price of $47.18, for a total transaction of $589,750.00. Following the sale, the director now owns 21,326 shares of the company’s stock, valued at $1,006,160.68. The disclosure for this sale can be found here. Insiders sold a total of 14,000 shares of company stock worth $660,860 over the last three months. Insiders own 27.10% of the company’s stock.

Amphastar Pharmaceuticals Profile

Amphastar Pharmaceuticals, Inc, a bio-pharmaceutical company, develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products in the United States, China, and France. It offers BAQSIMI, a nasal spray for the treatment of severe hypoglycemia; Primatene Mist, an over-the-counter epinephrine inhalation product for the temporary relief of mild symptoms of intermittent asthma; Enoxaparin, to prevent and treat deep vein thrombosis; REXTOVY and Naloxone for opioid overdose; Glucagon for injection emergency kit; and Cortrosyn, for use as a diagnostic agent in the screening of patients with adrenocortical insufficiency.